Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced the launch of its artificial intelligence-powered good manufacturing practices (GMP) manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform integrates the company’s proprietary PDAOAI technology with advanced robotics provided through a collaboration with TechForce Robotics, aiming to support pharmaceutical, biotechnology, and advanced therapeutics companies in modernizing manufacturing operations through AI-driven workflows, digital quality systems, and intelligent automation.
The platform is designed to handle electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions, and process monitoring. This announcement is significant as it represents a shift toward AI-enabled biomanufacturing, which could address persistent challenges in drug production, including high costs, inefficiencies, and regulatory compliance burdens. By automating critical GMP processes, Oncotelic aims to reduce human error, streamline regulatory oversight, and accelerate the time-to-market for new therapies.
Oncotelic will also showcase progress with its Deciparticle nanomedicine platform, including SAPU003, a clinical-stage intravenous everolimus program currently being evaluated in a Phase 1b study. This highlights the company’s broader strategy of leveraging AI across its pipeline and manufacturing operations. The platform is underpinned by Oncotelic’s relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, which provides a real-world environment for deploying PDAOAI.
The collaboration with TechForce Robotics brings purpose-built robotics and automation solutions tailored for pharmaceutical manufacturing. This partnership enhances the platform’s capability to integrate physical automation with digital intelligence, creating a comprehensive solution for GMP compliance and operational efficiency. The implications of this launch extend beyond Oncotelic, as it sets a precedent for AI adoption in regulated manufacturing environments, potentially influencing industry standards and regulatory expectations.
Oncotelic’s CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued U.S. patents, underscoring the company’s innovative foundation. The company also owns 45% of GMP Bio, a joint venture advancing its own pipeline of drug candidates that complement Oncotelic’s strategic position in oncology and rare disease therapeutics. For more information, visit www.oncotelic.com.
TechForce Robotics, the operating brand of Nightfood Holdings, Inc., designs and deploys robotics for service, hospitality, and pharmaceutical manufacturing applications. More details are available at www.techforcerobotics.com.
This launch at BIO 2026 underscores the growing intersection of AI and biomanufacturing, with potential to transform how drugs are produced, quality-controlled, and brought to patients. The platform’s success could pave the way for broader adoption of AI-driven GMP systems across the industry, improving drug availability and reducing costs.
